| Multiple Myeloma
Abecma vs Darzalex
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Abecma vs Darzalex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDarzalex has a higher rate of injection site reactions vs Abecma based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Darzalex but not Abecma, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Abecma
Darzalex
At A Glance
IV infusion
Single infusion
BCMA-directed CAR-T cell therapy
IV infusion
Weekly to every 4 weeks
Anti-CD38 monoclonal antibody
Indications
- Multiple Myeloma
- Multiple Myeloma
Dosing
Multiple Myeloma Lymphodepleting chemotherapy: cyclophosphamide 300 mg/m2 IV and fludarabine 30 mg/m2 IV for 3 days; administer ABECMA 300 to 510 x 10^6 CAR-positive T cells by IV infusion two days after completion of lymphodepleting chemotherapy; premedicate with acetaminophen and an H1-antihistamine approximately 30 to 60 minutes before infusion.
Multiple Myeloma 16 mg/kg IV; dosing schedule varies by combination regimen: weekly for initial doses (6-9 doses), then every 2-3 weeks, then every 4 weeks until disease progression; pre-medicate with corticosteroids, antipyretics, and antihistamines before each infusion.
Contraindications
—
- History of severe hypersensitivity (e.g., anaphylactic reactions) to daratumumab or any of the formulation components
Adverse Reactions
Most common (>=20%) CRS, pyrexia, any infection, febrile neutropenia, hypogammaglobulinemia, musculoskeletal pain, hypotension, infections-pathogen unspecified, fatigue, tachycardia, diarrhea, nausea, headache, encephalopathy, dyspnea, edema
Serious infections-pathogen unspecified, pneumonia, viral infections, encephalopathy, pyrexia, sepsis
Postmarketing Immune effector cell-associated neurotoxicity syndrome (ICANS), T cell malignancies
Most common (>=20%) Upper respiratory infection, neutropenia, infusion-related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, asthenia
Serious Pneumonia, infusion-related reactions (Grade 3-4), neutropenia, thrombocytopenia, febrile neutropenia, sepsis
Postmarketing Anaphylactic reaction, infusion-related reactions (including deaths), pancreatitis, cytomegalovirus, listeriosis
Pharmacology
ABECMA is a BCMA-directed CAR-positive T cell therapy; the CAR construct uses an anti-BCMA scFv-targeting domain linked to CD3-zeta and 4-1BB intracellular signaling domains, resulting in CAR-positive T cell proliferation, cytokine secretion, and cytolytic killing of BCMA-expressing plasma cells.
Anti-CD38 monoclonal antibody; daratumumab is an IgG1k human mAb that binds CD38 on tumor cells and induces apoptosis via Fc-mediated cross-linking and immune-mediated lysis through complement dependent cytotoxicity (CDC), antibody dependent cell mediated cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Abecma
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Darzalex
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Abecma
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Darzalex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Abecma
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Darzalex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCell Therapy 360 Patient Assistance Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Acute Lymphoblastic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AbecmaView full Abecma profile
DarzalexView full Darzalex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.